



PATENT

Docket No. 2026-4124US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Kawakami, et al.

Group Art Unit: 1642

Serial No. : 08/417,174

Examiner: Huff, S.

Filed : April 5, 1995

For : MELANOMA ANTIGENS AND THEIR USE IN
DIAGNOSTICS AND THERAPEUTIC METHODS

#16/E
(NE)
4/15/98

RESPONSE TO OFFICIAL ACTION PURSUANT TO 37 C.F.R. §1.116

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231
Attn: Box AF

RECEIVED
APR 24 1998
GROUP 1800

Sir:

In response to the Official Action dated January 5, 1998, applicants respectfully request reconsideration in view of the following amendment and remarks.

IN THE CLAIMS

29. (amended) A pharmaceutical composition comprising an effective amount of gp100 (SEQ ID NO:27) or the peptides of claim 15 or claim 22 and a[n] pharmacologically acceptable excipient, diluent or carrier.

30. (amended) A method of treating melanoma in a mammal comprising administering a pharmaceutical composition comprising gp100 (SEQ ID NO:27) or [an immunogenic peptide fragment thereof] the peptide of claim 15 or claim 22 to said mammal in an effective amount to stimulate the production of immune cells.

DO NOT enter
STH